IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice.

Alcoholic liver disease (ALD) is characterized by steatosis and upregulation of proinflammatory cytokines, including IL-1β. IL-1β, type I IL-1 receptor (IL-1R1), and IL-1 receptor antagonist (IL-1Ra) are all important regulators of the IL-1 signaling complex, which plays a role in inflammation. Furthermore, IL-1β maturation is dependent on caspase-1 (Casp-1). Using IL-1Ra-treated mice as well as 3 mouse models deficient in regulators of IL-1β activation (Casp-1 and ASC) or signaling (IL-1R1), we found that IL-1β signaling is required for the development of alcohol-induced liver steatosis, inflammation, and injury. Increased IL-1β was due to upregulation of Casp-1 activity and inflammasome activation. The pathogenic role of IL-1 signaling in ALD was attributable to the activation of the inflammasome in BM-derived Kupffer cells. Importantly, in vivo intervention with a recombinant IL-1Ra blocked IL-1 signaling and markedly attenuated alcohol-induced liver inflammation, steatosis, and damage. Furthermore, physiological doses of IL-1β induced steatosis, increased the inflammatory and prosteatotic chemokine MCP-1 in hepatocytes, and augmented TLR4-dependent upregulation of inflammatory signaling in macrophages. In conclusion, we demonstrated that Casp-1-dependent upregulation of IL-1β and signaling mediated by IL-1R1 are crucial in ALD pathogenesis. Our findings suggest a potential role of IL-1R1 inhibition in the treatment of ALD.

[1]  D. Eizirik,et al.  IL‐1 receptor antagonist inhibits recurrence of disease after syngeneic pancreatic islet transplantation to spontaneously diabetic non‐obese diabetic (NOD) mice , 1997, Clinical and experimental immunology.

[2]  C. McClain,et al.  Dysregulated cytokine metabolism, altered hepatic methionine metabolism and proteasome dysfunction in alcoholic liver disease. , 2005, Alcoholism, clinical and experimental research.

[3]  M. Luster,et al.  Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat , 1997, Hepatology.

[4]  F. Sutterwala,et al.  Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. , 2009, The Journal of clinical investigation.

[5]  A. Dolganiuc,et al.  Bone marrow–derived immune cells mediate sensitization to liver injury in a myeloid differentiation factor 88–dependent fashion , 2008, Hepatology.

[6]  M. Cachin,et al.  [Acute alcoholic hepatitis]. , 1971, Annales de medecine interne.

[7]  W. Owen,et al.  Phenotypic and functional characteristics of macrophage‐like cells differentiated in pro‐inflammatory cytokine‐containing cultures , 2000, Immunology and cell biology.

[8]  J. Devière,et al.  The interleukin‐17 pathway is involved in human alcoholic liver disease , 2009, Hepatology.

[9]  C. Dinarello,et al.  Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes. , 1992, Blood.

[10]  V. Serre-Beinier,et al.  Interleukin-1 Receptor Antagonist Modulates the Early Phase of Liver Regeneration after Partial Hepatectomy in Mice , 2011, PloS one.

[11]  A. Dolganiuc,et al.  Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells , 2011, Hepatology.

[12]  D. Brenner,et al.  Innate immunity in alcoholic liver disease. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[13]  J. Mier,et al.  Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. , 1992, Cytokine.

[14]  K. Herholz,et al.  Biodistribution, pharmacokinetics and metabolism of interleukin‐1 receptor antagonist (IL‐1RA) using [18F]‐IL1RA and PET imaging in rats , 2011, British journal of pharmacology.

[15]  N. Kaplowitz,et al.  Current concepts and controversies in the treatment of alcoholic hepatitis. , 2006, World journal of gastroenterology.

[16]  Matthias Schneider,et al.  Infections in patients with rheumatoid arthritis treated with biologic agents. , 2005, Arthritis and rheumatism.

[17]  C. Chan,et al.  Serum levels of interleukin-8 in alcoholic liver disease: relationship with disease stage, biochemical parameters and survival. , 1996, Journal of hepatology.

[18]  Effects of alcohol and oxidative stress on liver pathology: the role of the mitochondrion. , 2002, Alcoholism, clinical and experimental research.

[19]  T. Luedde,et al.  Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury , 2011, Gut.

[20]  A. Dolganiuc,et al.  The critical role of toll‐like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88 , 2008, Hepatology.

[21]  D. Lauffenburger,et al.  An inducible autocrine cascade regulates rat hepatocyte proliferation and apoptosis responses to tumor necrosis factor‐α , 2008, Hepatology.

[22]  Melinda Fitzgerald,et al.  Immunol. Cell Biol. , 1995 .

[23]  Ya-ping Zhang,et al.  Role of c‐Jun N‐terminal kinase and p38/activation protein‐1 in interleukin‐1β‐mediated type I collagen synthesis in rat hepatic stellate cells , 2012, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[24]  G. Arteel,et al.  Toll‐like receptor 4 is involved in the mechanism of early alcohol‐induced liver injury in mice , 2001, Hepatology.

[25]  H. K. Bojes,et al.  Inactivation of Kupffer cells prevents early alcohol‐induced liver injury , 1994, Hepatology.

[26]  S. Grossman,et al.  Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells: a model of age-related tumorigenesis in mice. , 2007, Cancer research.

[27]  P. Broët,et al.  A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis , 2004, Hepatology.

[28]  K. Kodys,et al.  Up-regulation of MicroRNA-155 in Macrophages Contributes to Increased Tumor Necrosis Factor α (TNFα) Production via Increased mRNA Half-life in Alcoholic Liver Disease* , 2010, The Journal of Biological Chemistry.

[29]  S. Opal,et al.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. , 1997, Critical care medicine.

[30]  P. Mandrekar,et al.  A recent perspective on alcohol, immunity, and host defense. , 2009, Alcoholism, clinical and experimental research.

[31]  S. Akira,et al.  Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. , 2011, Immunity.

[32]  R. Thurman,et al.  Antibiotics prevent liver injury in rats following long-term exposure to ethanol. , 1995, Gastroenterology.

[33]  J. Singh,et al.  Anakinra for rheumatoid arthritis. , 2009, The Cochrane database of systematic reviews.

[34]  V. Pazienza,et al.  Monocyte chemoattractant protein‐1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes , 2008, Hepatology.

[35]  C. Dinarello,et al.  Immunological and inflammatory functions of the interleukin-1 family. , 2009, Annual review of immunology.

[36]  R. Thurman.  II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. , 1998, American Journal of Physiology.

[37]  C. Dinarello,et al.  Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: II. IL-1 receptor antagonist inhibits lipopolysaccharide-induced cytokine synthesis by human monocytes. , 1992, Blood.

[38]  C. Bode,et al.  Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. , 1987, Journal of hepatology.

[39]  K. Wallace,et al.  Interleukin-1 participates in the progression from liver injury to fibrosis. , 2009, American Journal of Physiology - Gastrointestinal and Liver Physiology.

[40]  D. Brenner,et al.  Clinical Syndromes of Alcoholic Liver Disease , 2006, Digestive Diseases.

[41]  G. Gores,et al.  A Pilot Study of the Safety and Tolerability of Etanercept in Patients with Alcoholic Hepatitis , 2004, American Journal of Gastroenterology.

[42]  B. Monsarrat,et al.  IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G , 2012, Proceedings of the National Academy of Sciences.

[43]  V. Purohit,et al.  Molecular mechanisms of alcoholic fatty liver. , 2009, Alcoholism: Clinical and Experimental Research.

[44]  H. Tilg,et al.  Serum levels of cytokines in chronic liver diseases. , 1992, Gastroenterology.

[45]  J. Hoek,et al.  Ethanol potentiates tumor necrosis factor‐α cytotoxicity in hepatoma cells and primary rat hepatocytes by promoting induction of the mitochondrial permeability transition , 2000, Hepatology.

[46]  P. Mandal,et al.  Anti-inflammatory pathways and alcoholic liver disease: role of an adiponectin/interleukin-10/heme oxygenase-1 pathway. , 2010, World journal of gastroenterology.

[47]  I. Deaciuc,et al.  Kupffer cell inactivation prevents lipopolysaccharide‐induced structural changes in the rat liver sinusoid: An electron‐microscopic study , 1996, Hepatology.

[48]  D. Brenner,et al.  Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. , 2010, Gastroenterology.

[49]  C. Dinarello.  Interleukin-1beta and the autoinflammatory diseases. , 2009, The New England journal of medicine.

[50]  M. Dougados,et al.  Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials , 2008, Annals of the rheumatic diseases.

[51]  R. Thurman,et al.  II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. , 1998, American Journal of Physiology - Gastrointestinal and Liver Physiology.

[52]  R. Tompkins,et al.  A bioartificial liver device secreting interleukin-1 receptor antagonist for the treatment of hepatic failure in rats. , 2007, The Journal of surgical research.

[53]  C. McClain,et al.  Tumor necrosis factor and alcoholic liver disease. , 1998, Alcoholism, clinical and experimental research.

[54]  A. Dolganiuc,et al.  Type I interferons protect from Toll-like receptor 9-associated liver injury and regulate IL-1 receptor antagonist in mice. , 2011, Gastroenterology.

[55]  J. Tschopp,et al.  The Inflammasomes , 2010, Cell.

[56]  P. Mandrekar,et al.  An essential role for monocyte chemoattractant protein‐1 in alcoholic liver injury: Regulation of proinflammatory cytokines and hepatic steatosis in mice , 2011, Hepatology.

[57]  H. Ishii,et al.  [Alcoholic liver disease]. , 2019, Ryoikibetsu shokogun shirizu.

[58]  C. Dinarello,et al.  The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. , 2004, Proceedings of the National Academy of Sciences of the United States of America.